![pageSearch](/themes/hestia/images/page-search.webp)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
Jul 16, 2023Her Symptoms Suggested Long Covid. But Was That Too Obvious?
May 03, 2023Lysosomal
Apr 13, 2023Biochemical Reagents Market 2023 Unveiling Future Growth, Explores New Trends and Forecasts
Mar 16, 2023US FDA approves Cue Health’s at
Apr 27, 2023US FDA approves Cue Health’s at
![Apr 27, 2023](/themes/hestia/images/news-details-icon1.webp)
(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Cue Health's at-home COVID-19 test, the first coronavirus test to get marketing authorization using a traditional premarket review, the agency said.
The FDA said this was the first ever at-home test authorized using the traditional review process for any respiratory illness.
"This is part of the FDA's broader effort to advance the development and availability of at-home tests for a variety of medical conditions to expand patient access to testing," FDA official Jeff Shuren said in a statement.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri)